Group 1 - The Jiangsu Suhao Artificial Intelligence Application Innovation Industry Special Fund (Limited Partnership) has been established with a total investment of 1 billion yuan [1] - The fund's operational scope includes equity investment, investment activities using self-owned funds, and venture capital limited to investing in unlisted companies [1] - The fund is jointly funded by Jiangsu Suhao Holding Group Co., Ltd. and Jiangsu Strategic Emerging Industry Mother Fund Co., Ltd. among others [1]

Core Viewpoint - Nais Group's green low-carbon detergent technology has been recognized by the Ministry of Industry and Information Technology, showcasing a commitment to sustainable development through the use of over 92% natural ingredients, replacing traditional petroleum-based materials [1][2] Group 1: Green Technology and Innovation - The company has implemented a comprehensive transformation towards high-quality green low-carbon products, with over 90% of its products undergoing green upgrades [2][3] - Nais has developed a new concentrated laundry detergent with an active ingredient content of 48%, three times the national standard, enhancing environmental efficiency through reduced packaging and simplified design [2][3] - The company has established a national-level key laboratory for detergents and has been involved in drafting the first low-carbon product industry standards in the daily chemical sector [3] Group 2: Global Expansion Strategy - Nais is pursuing a dual-circulation strategy focusing on both domestic and international markets, enhancing the global influence of Chinese products [4][5] - The company has established overseas production bases, including the first factory in Angola, and is expanding its footprint in various countries, including Uganda and Egypt [5][6] - Nais is integrating global research resources to drive technological innovation in green development, collaborating with international industry leaders in various fields [6][8] Group 3: Ecological Transformation - The "Ecological Nais" initiative aims to create a new industrial system that integrates ecological research, product development, and consumer experience [7][8] - The company is focusing on developing a beautiful and healthy industry by leveraging advanced technologies and resources to enhance product offerings [8] - Nais is committed to meeting and leading high-quality consumer demands through innovative practices and new industry explorations [8]

Group 1 - Central enterprises are required to enhance the revenue share of strategic emerging industries under the premise of adapting to local conditions [1] - The State-owned Assets Supervision and Administration Commission (SASAC) plans to implement a doubling investment initiative for strategic emerging industries this year [1] - Local state-owned enterprises are also setting clear plans and goals to increase their focus on strategic emerging and future industries [1] Group 2 - The government work report emphasizes the need to develop new productive forces and modern industrial systems, with specific measures to cultivate emerging and future industries [2] - There is a strong focus on original technology development, with leading tech companies encouraged to spearhead major breakthroughs and form upgraded innovation coalitions [2] - Local governments, such as Hebei, are setting hard targets for enhancing independent innovation capabilities, including a 70% investment ratio in major research projects [2] Group 3 - Under policy guidance, "increased efforts" is a key theme for state-owned enterprises to transition towards new industries this year [3] - Heilongjiang aims for strategic emerging industries to account for over 20% of investment and revenue by the end of 2025, doubling from 2022 [3] - Gansu is focusing on developing new materials, renewable energy, and other strategic emerging industries while leveraging its unique advantages [3]

Group 1 - The central government emphasizes the need for state-owned enterprises to enhance the revenue share of strategic emerging industries while adopting various models such as self-cultivation, strategic alliances, and investment platforms [1][2] - The State-owned Assets Supervision and Administration Commission (SASAC) plans to implement a doubling investment initiative for strategic emerging industries this year, with clear targets set for both central and local state-owned enterprises [1][3] - Local governments, such as Zhejiang and Hebei, are actively working on enhancing innovation capabilities and setting specific targets for R&D investment and technology transfer rates [2][3] Group 2 - The focus on "new" industries is a key theme for state-owned enterprises this year, with provinces like Heilongjiang and Guizhou aiming for significant increases in investment and revenue from strategic emerging industries by 2025 [3] - Companies like China Aluminum Group are prioritizing the development of strategic emerging industries and future industries, with ambitious growth targets for investment and revenue in new materials and renewable energy [3]

Group 1 - The core viewpoint emphasizes the importance of developing strategic emerging industries through various methods such as independent cultivation, strategic alliances, equity cooperation, and investment platform creation [1] - There is a call to accelerate the development of future industries and actively compete in the "future arena" [1] - Chain-leading enterprises are encouraged to play a greater role in strengthening and supplementing supply chains [1]

证券代码：300832 证券简称：新产业 公告编号：2025-012 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 1项国家知识产权局、3项日本特许厅颁发的《发明专利证书》，现将本次取得的 发明专利具体情况公告如下： 1、发明名称：试剂组合以及免离心的全血中目标免疫抑制剂的检测方法 中国专利号：ZL202311861025.6 专利权人：深圳市新产业生物医学工程股份有限公司 发明人：饶捷、李婷华、张云、罗春、郑文迪、徐红 专利申请日：2023年12月31日 授权公告日：2025年03月07日 上述专利保护技术为公司自主研发，本发明涉及体外检测技术领域，具体涉 及在全血中检测免疫抑制剂，通过优化全血处理剂的组分并结合小分子夹心法检 测技术，实现免离心检测，且检测结果能与质谱检测结果保持高度一致，极大提 高了检测效率。 深圳市新产业生物医学工程股份有限公司 关于公司获得发明专利证书的公告 1 上述专利保护技术为公司自主研发，本发明应用于公司全自动核酸检测分析 仪器Molecision R8，涉及 ...

证券代码：300832 证券简称：新产业 公告编号：2025-011 深圳市新产业生物医学工程股份有限公司 关于控股股东部分股份办理质押及实际控制人部分股份解除质押 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 公司控股股东西藏新产业投资管理有限公司（以下简称"西藏新产业"）和实际 控制人翁先定先生的函告，获悉西藏新产业所持有的公司 720 万股股份办理了质 押手续；另，翁先定先生已质押给国投证券资产管理有限公司（原名：安信证券 资产管理有限公司）的其所持有的公司 790 万股股份办理了解除质押手续。具体 事项如下： 二、 公司实控人部分质押股份解除质押的基本情况 | 股东 名称 | 是否为控股股东 或第一大股东及 | 本次解除质 押股份数量 | 占其所持 股份比例 | 占公司总 股本比例 | 质押 起始日 | | 质押 解除日 | | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 其一 ...

证券代码：300832 证券简称：新产业 公告编号：2025-010 深圳市新产业生物医学工程股份有限公司 关于持股 5%以上股东股份减持计划的预披露公告 持股 5%以上的股东天津红杉聚业股权投资合伙企业（有限合伙）保证向本 公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证本公告内容与信息披露义务人提供的信息一 致。 特别提示： 深圳市新产业生物医学工程股份有限公司（以下简称"公司"或"新产业"） 于近日收到公司持股 5%以上的股东天津红杉聚业股权投资合伙企业（有限合伙） （以下简称"红杉聚业"或"天津红杉"）出具的《关于新产业股份减持计划的 告知函》。 红杉聚业于 2011 年完成对公司的投资，是公司自设立以来首轮融资中唯一 的创投机构，投资期长达 13 年。红杉聚业持有本公司股份 91,311,250 股（占本 公司总股本的 11.6214%），该部分股份已于 2023 年 5 月 12 日解除限售并上市流 通。红杉聚业计划自本减持计划公告之日起 15 个交易日后的 3 个月内通过大宗 交易方式减持本公司股份不超过公司总股本的 1%（按公司截至告知函出具 ...

近日，深圳市新产业生物医学工程股份有限公司（以下简称"公司"）乙型 肝炎病毒表面抗原测定试剂盒（磁微粒化学发光法）获得了由欧盟公告机构-TÜV 南德意志集团签发的IVDR CE最高风险等级Class D认证证书，具体获证情况如 下： 证券代码：300832 证券简称：新产业 公告编号：2025-009 深圳市新产业生物医学工程股份有限公司 关于公司产品获得 IVDR CE 认证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、 获证产品的基本信息 | 产品名称 | 有效期 | 证书编号 | 临床用途 | | --- | --- | --- | --- | | HBsAg (CLIA) 乙型肝炎病毒表面抗原测 | 有效期至 2025-12-14 | No. V10 105113 0008 Rev. 01 | 用于乙型肝炎病毒感 染的辅助诊断以及血 | | 定试剂盒（磁微粒化学发 | | | 液筛查。 | | 光法） | 有效期至 | No. V70 105113 | | | | 2030-03-02 | 0010 Rev. 00 | | 二、 对公司的 ...

Group 1 - The China Securities Regulatory Commission (CSRC) aims to enhance the Beijing Stock Exchange (BSE) as a leading international securities exchange, focusing on supporting innovative small and medium-sized enterprises (SMEs) [1] - The CSRC plans to strengthen the responsibilities of intermediary institutions and improve the quality of listed companies by enhancing regulatory mechanisms and coordination between on-site and off-site supervision [1] - The CSRC intends to optimize the investor structure by attracting more long-term funds and guiding public funds to invest in the BSE [1] Group 2 - The CSRC will support the listing of qualified biopharmaceutical and traditional Chinese medicine companies on the New Third Board and BSE to seize development opportunities [2] - The CSRC emphasizes the importance of capital markets in supporting the development of the technology innovation industry, promoting high-quality development of technology innovation bonds [2] - The CSRC aims to enhance the role of private equity funds in serving the real economy and technology innovation by improving valuation standards and information disclosure systems [2] Group 3 - The CSRC plans to optimize the interconnection between mainland and Hong Kong financial markets, enhancing mechanisms such as Stock Connect and Bond Connect [3] - The CSRC will explore the feasibility of Hong Kong companies listing in mainland markets based on market demand [3] - The CSRC aims to promote the optimization of cross-border wealth management pilot programs [3]